UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
May 17, 2016
Date of Report (Date of earliest event reported)
 
Flex Pharma, Inc.
(Exact name of registrant as specified in its charter)

 	 	 	 	 	
Delaware	 	001-36812	 	46-5087339	
(State or other jurisdiction	 	(Commission File Number)	 	(IRS Employer Identification No.)	
of incorporation)	 	 	 	 	

 	 	 	
800 Boylston Street, 24th Floor
Boston, MA	 	02199	
(Address of principal executive offices)	 	(Zip Code)	
 
Registrant’s telephone number, including area code: (617) 874-1821
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 
o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

A copy of the slide presentation that will be used by representatives of Flex Pharma, Inc. (the "Company") in connection with investor meetings or presentations from time to time (the "Corporate Presentation") is attached to this Current Report on Form 8-K as Exhibit 99.1. The Corporate Presentation is current as of May 17, 2016, and the Company disclaims any obligation to correct or update this material in the future.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.Financial Statements and Exhibits.
 
(d)                                 Exhibits

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:

 	
 	 	 	 	
Exhibit No.	 	Description	
99.1	
 	 	Corporate Presentation current as of May 17, 2016	

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	 	 	
 	Flex Pharma, Inc.	
 	 	
Dated: May 17, 2016	 	
 	By:	/s/ Robert Hadfield	
 	 	Robert Hadfield	
 	 	General Counsel and Secretary	

INDEX TO EXHIBITS

 	 	 	 	
Exhibit No.	 	Description	
99.1	
 	 	Corporate Presentation current as of May 17, 2016	

1 Novel Treatments for Neuromuscular Conditions May 2016 NASDAQ: FLKS

 

2 Any statements in this presentation and the oral commentary about future expectations, plans and prospects for the company, including statements about the company’s strategy, future operations, development of its consumer and drug product candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “approximately,” “development plans,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the company’s clinical studies; the uncertainties inherent in conducting clinical studies; results from our ongoing and planned preclinical development; expectations of our ability to make regulatory filings and obtain and maintain regulatory approvals, our ability to develop and commercialize our consumer products; anticipated positioning and product attributes of our consumer products; results of early clinical studies as indicative of the results of future trials; availability of funding sufficient for the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the company’s consumer or drug product candidates; the inherent uncertainties associated with intellectual property; and other factors discussed in the Risk Factors set forth in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) and in other filings the company makes with the SEC from time to time. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by the company relating to market size and growth and other data about the company’s industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of the company’s future performance and the future performance of the markets in which the company operates are necessarily subject to a high degree of uncertainty and risk. This presentation contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this presentation, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Forward-Looking Statements

 

3 •  Developing innovative and proprietary treatments for a broad range of painful and debilitating cramps and spasms •  Novel insights regarding neuromuscular physiology from our co-founders (ion channels and TRP biology, MacKinnon Nobel Prize 2003; NAS members) form the basis of our development efforts •  Nocturnal Leg Cramps: positive human efficacy in a randomized, blinded, controlled cross-over study with statistically significant effects (p<0.05) demonstrated on multiple efficacy endpoints •  Muscle cramps in athletes: statistically significant benefit in a randomized, double-blinded, vehicle-controlled crossover study by Penn State •  Next studies in NLC, MS and ALS with synthesized single agent -- TRPA1 and TRPV1 agonist -- initiating in 2016 Flex Pharma Overview Exercise Associated Muscle Cramps Nocturnal Leg Cramps MS, ALS, etc

 

4 Management Team •  Christoph Westphal, MD PhD, CEO; Cofounder/Lead investor ALNY MNTA XLRN SIRT Alnara CNCE VSTM OVAS •  Jennifer Cermak, PhD, Cofounder, VP R&D; Sirtris, Glaxo SmithKline, United Therapeutics, Pfizer •  Rob Hadfield, General Counsel; Cooley LLP, Kiva Systems, SG Cowen •  Marina Hahn, President, Consumer Goods; Spirits Marque One (SVEDKA vodka), William Morris, Pepsi •  Kathie Lindemann, COO; DAVIDs TEA, Starbucks •  John McCabe, VP Finance; Ariad, Charles River Associates, Biogen, Arthur Andersen •  Laura Rosen, MD PhD; AstraZeneca, Shire, Merck •  Angelene Simonello, VP Corporate and Program Development; Viacell, Biogen •  Thomas Wessel, MD PhD, CMO; JNJ (Razadyne®), SEPR (Lunesta®), ACOR (Ampyra®) •  Elizabeth Woo, SVP, Investor Relations; Biogen, Ironwood, Cubist Board of Directors •  Jeff Capello, former CFO Ortho-Clinical Diagnostics; BOD OVAS, former Boston Scientific CFO, PKI, PWC •  Peter Barton Hutt, former Chief Counsel FDA; Sirtris, Momenta, Concert, Covington and Burling •  Marc Kozin, LEK Consulting, former President of North American practice; BOD OVAS, ECYT, DYAX, UFPT •  Rod MacKinnon, MD, Co-founder, Chair, SAB; Nobel Prize 2003, ion channels; Professor, Rockefeller; NAS •  Rob Perez, former CEO Cubist; former Biogen, BOD AMAG, CDTX •  Stuart Randle, Ivenix CEO, former CEO GI Dynamics, former CEO ACT Medical, Baxter •  John Sculley, former CEO Pepsi (current owner of Gatorade), former CEO Apple •  Michelle Stacy, former Keurig President, Gillette/P&G, BOD iRobot Management Team and Board of Directors

 

5 Sports Team investors Wyc Grousbeck, Managing Partner, Governor, CEO Boston Celtics KPC Venture Capital (Kraft family), Owner New England Patriots, New England Revolution PagsGroup (Steve Pagliuca), Managing Partner, Bain Capital; Managing Partner, Boston Celtics Mark Wan, Causeway Partners; Minority Owner: Boston Celtics, SF 49ers Christoph Westphal, Minority Owner Boston Celtics Biotech investors Rick Beleson, retired SVP, Capital Research Co Peter Lynch, Trustee, The Lynch Foundation John Maraganore, PhD, Biogen, MLNM, CEO Alnylam Scientific Advisory Board Rod MacKinnon, MD, Cofounder, Chair, SAB; Nobel Prize 2003, ion channels; Professor, Rockefeller; National Academy of Science (NAS) Bruce Bean, PhD, Cofounder, Chair, SAB; Winthrop Professor, Harvard Med; Neurophysiology; NAS Alfred Sandrock, MD, PhD; Neurologist, Chief Medical Officer of Biogen Roger Tung, PhD; Medicinal chemist, Vertex, Merck (inventor multiple drugs); CEO, Concert Chris Walsh, PhD; Professor Emeritus, Harvard Med; Genzyme, Verastem, Sirtris; NAS John Winkelman, MD, PhD; Chief Sleep Disorders, MGH; BWH, RLS clinical development Scientific Advisory Board & Select Investors

 

6 Large and Diverse Market Opportunities Exercise Associated Muscle Cramps (EAMCs) U.S. Market •  Initial target: athletes engaging in high-intensity sports •  Potential future targets: casual sports participants Consumer Brand Prescription Drug Nocturnal Leg Cramps Sudden painful contraction reducing sleep quality No drug approved in the U.S. U.S. Patient Population •  37% prevalence for 50+ yo1 •  ~4M over 65 yo suffer daily2 1 Naylor & Young, A General Population Survey of Rest Cramps, Age and Ageing 1994.23 418-420 2 Management estimates based on third party survey results 3 National Institute of Neurological Disorders and Stroke 4 Morbidity and Mortality Weekly Report July 2014 Spasticity in Severe Neuromuscular Conditions Multiple Sclerosis, ALS/Motor Neuron Disease U.S. Patient Population •  MS: 250K – 350K patients3 •  ALS: 12K patients4

 

7 Flex Pharma Development Path ANTICIPATED TIMELINE FLX-787 Single agent TRP activator Nocturnal Leg Cramps (NLC) Multiple Sclerosis (MS) Amyotrophic Lateral Sclerosis (ALS) Phase 2B^ Human POC* Phase 3 Program Phase 2 Australia Phase 2 Australia All Studies are randomized, controlled, blinded *Study conducted under dietary supplement guidelines. Single agent TRP activator referred to as BV-164 for this study. ^ Subject to FDA review of IND application

 

8 Neurogenic Origin of Muscle Cramping/Spasms Cramps and spasms are generally NOT caused by dehydration, lactic acid build-up or electrolyte imbalances affecting the muscle •  Muscle cramping is caused by excessive firing of alpha-motor neurons in the spinal cord, which trigger a painful contraction of the muscle •  Repetitive muscle use induces hyperexcitability of alpha-motor neurons, causing them to fire excessively and trigger cramping Alpha-motor neuron Hyperexcitability of alpha-motor neurons is also a likely basis for spasticity and spasms

 

9 TRP Ion Channel Co-crystal Structures – Flex Drug Targets in Two Recent Nature Papers C.E. Paulsen, J. Armache, Y. Gao, Y. Cheng and D. Julius, Nature, 8 April 2015 E. Cao, M. Liao, Y. Cheng and D. Julius, Nature, 5 Dec 2013 TRPA1 TRPV1

 

10 Therapeutic Mechanism: Chemical Neuro Stimulation

 

11 NLC Proof-of-Concept Study of Extract Formulation •  Randomized, blinded, controlled, cross-over design with extract formulation •  Evaluated 50 healthy subjects (50-77 years of age) who experienced nocturnal leg cramps at least four nights per week. Placebo Run-in: 2 weeks followed by randomization Period 1 FLX-product (2 weeks) Period 2 FLX-product (2 weeks) Period 1 Placebo (2 weeks) Period 2 Placebo (2 weeks) Exclude Placebo Responders ★ ★ ★ ★ ★ Study Visit 50 subjects evaluated ★ Recruitment and Screening (cramps for ≥ 4 nights per week for 4 consecutive weeks prior to Screening)

 

12 Selected for podium presentation at AAN 2016 (only 1 of 14 late-breakers) •  Statistically significant effects demonstrated on multiple efficacy endpoints AAN 2016: Selected for Late-Breaking Presentation Positive Human Efficacy in Nocturnal Leg Cramps Figure 5. Percentage of participants who experienced at least a 25%, 50%, or 75% decrease in the total number of cramps over the two week study period. Those individuals receiving TRP-Stim demonstrated a more pronounced cramp reduction than Placebo in all groups, with only TRP-Stim showing a >75% reduction. •  The positive effects were seen across a broad range of enrolled subjects; in addition, a subset of patients showed pronounced benefit. Patient benefit appears clinically meaningful.

 

13 •  Treatment with TRP activators resulted in statistically significant effects on clinically meaningful endpoints:   cramp frequency (p<0.05)   cramp-free days (p<0.01)   physician-rated Clinical Global Impression of Change (p<0.01)   “difficulty staying asleep” (p<0.05)   VAS pain intensity over the last 3 days of each treatment period (p<0.01) •  The magnitude of efficacy in this study on reduction in muscle cramps appears similar to published “Class 1 level” quinine efficacy studies. •  Extract formulation was safe and well-tolerated; no SAEs reported. •  Chemical Neuro Stimulation of TRPV1 and TRPA1 channels in the oral mucosa may be a generally applicable method to treat disorders stemming from α-motor neuron hyperexcitability. AAN 2016: Summary & Conclusions

 

14 Human Efficacy: Synthesized Single Molecules & No Measurable Systemic Exposure Presented at ECTRIMS and Society for Neuroscience, October 2015 •  In normal healthy volunteers (n=9), cramps were electrically elicited, followed by 1h and 2h measurements after dosing •  Treatment arms of synthesized single agents FLX-787 & FLX-788 capable of activating both TRPA1 and TRPV1 strongly, statistically significantly reduced human cramp intensity relative to vehicle control •  Both FLX-787 and FLX-788 provided a significant 2-fold improvement in efficacy compared to the original extract formulation •  Initial Human PK (n=2) indicates no measurable systemic exposure; Parent form not detectable in plasma FLX-787 & FLX-788 significantly reduce muscle cramping in humans Ve hi cl e Ex tra ct F or m ul at io n FL X- 78 8 FL X- 78 7 0.0 0.5 1.0 1.5 2.0 R at io A U C (T re at m en t/B as el in e)

 

15 Oral Disintegrating Tablet (ODT)

 

16 Unmet Need •  Sudden painful contractions negatively impacting sleep and quality of life •  No drug approved in the U.S. In 1994, FDA banned use of quinine for treatment of leg cramps due to association with serious and life-threatening adverse events (primarily thrombocytopenia) Affected U.S. Population •  37% prevalence for 50+ yo1 •  Approximately 4M people over 65 yo suffer daily2 •  NLC population increasing dramatically given aging US demographics Significant Demand •  4.5 Million Quinine sulfate prescriptions in 2013 in UK (1/5 of the US population) NLC Market Opportunity 1 Naylor & Young, A General Population Survey of Rest Cramps, Age and Ageing 1994.23 418-420 2 Management estimates based on third party survey results *Two published studies of quinine treatment in muscle cramps that were categorized as Class I level of evidence by Katzberg et al for the American Academy of Neurology in 2010: •  Randomised controlled trial of hydroquinine in muscle cramps. Jansen et al, Lancet 1997; 349: 528-32. •  Effectiveness of quinine in treating muscle cramps: a double-blind, placebo-controlled, parallel-group, multicentre trial. Diener et al. Int J Clin Pract. 2002 May;56(4):243-6. Comprehensive meta-analysis of quinine studies by the Cochrane Collaboration in 2010.

 

17 MS ALS Traumatic brain injury Spinal cord injury Post-stroke Potential across Many Indications •  Muscle cramps is a common occurrence in healthy and neurological populations •  Large unmet medical need, not covered by quinine or other drugs like benzodiazepines •  Chemical Neuro Stimulation implies topical application and rapid reflex-like response •  Expect minimal to no systemic exposure, no anticipated drug-drug interactions, good option for polypharmacy patients Nocturnal Leg Cramps Dystonias Cramp fasciculation syndrome Dialysis induced Spasmodic dysphonia Neuropathy Parkinson’s Cerebral palsy

 

18 Upcoming Milestones ü  Feb: Results of NLC study with extract formulation ü  Apr 19: Late-breaking NLC results selected by AAN for podium presentation •  Q2 2016: Consumer product limited launch in 3 markets •  2016: Initiate MS study ex-US with FLX-787, subject to regulatory approval •  2016: Initiate ALS study ex-US with FLX-787, subject to regulatory approval •  2016: Initiate single agent NLC study •  H1 2017: IND filing

 

19 å Introducing a groundbreaking category-defining product that solves a medical mystery Flex Pharma Consumer Brand

 

20 Breakthrough, Efficacious PRODUCT + Culturally Relevant, magnetic LIFESTYLE BRAND HUGE OPPORTUNITY The Equation

 

21 HERETICAL BELIEF SYSTEM ADDRESSING A LATENT NEED EVANGELIZING SUBCULTURE INTENSELY PERSUASIVE INSPIRING ORIGIN STORY COMMUNITY BUILDING IT’S THE NERVE Building a Cult Brand

 

22 Heretical Belief System Existing “remedies” – that claim to treat the muscle – do not work

 

23 are control freaks is defined by their sport is uber confident body betrays them loss of control loss of identity humiliation A loss of power, achievement, and control for people who are obsessed with all three – and, perhaps, further humiliation since cramps are (falsely) associated with failure to train properly Potential for a high level of emotional engagement THE TARGET THE MUSCLE CRAMP over achieves achievement prevention want to be immortal The Latent Need

 

24 High propensity for muscle cramps –  We estimate 17 million endurance athletes in the US (ages 18+) experience muscle cramps monthly High consequence for cramping: –  A performance killer Experimenters –  Constant quest for new products to control their body’s performance Affluent –  Willing to pay a premium Tight subcultures –  High levels of peer-to-peer knowledge sharing Event driven –  Great for 1-to-1 marketing Growing, trending market –  Especially cycling and triathlons Evangelizing Subculture

 

25 Target Evolution MAINSTREAM CASUAL ATHLETES OTHER ENDURANCE ATHLETES ASPIRATIONAL (ALPHA HUMANS)

 

26 PRODUCT -  50ml -  Scientifically Proven to Treat & Prevent Cramps -  Certified NSF, USDA Organic, non-GMO, Gluten-free, Kosher FOUNDER - Endurance Athlete - Nobel-prize Winner EVIDENCE -  Real Athlete Testimonials -  Scientific Research + PSU Athletic cramp model Intensely Persuasive COMING SOON

 

27 Figure 5. Integrated EMG signal. Area under the curve for cramp intensity-duration curve. Representative of total muscle activity during cramp. Integrated EMG signal was significantly lower in A compared to V (p=0.01). Dashed red line indicates the mean value for the final preconditioning trial. A V 0 .0 0 .5 1 .0 1 .5 2 .0 2 .5 In te g r a te d E M G v o lt s · s A V 0 .0 0 .2 0 .4 0 .6 0 .8 1 .0 In te g r a te d E M G v o lt s · s * •  Self-induced cramp model: 1.  Triceps surae placed in pre-shortened position. 2.  Maximal voluntary isometric contraction of triceps surae until initiation of cramp (up to 90 seconds). •  Upon cramp initiation, subject halted MVC, remained still and relaxed until cessation of the muscle cramp. Figure 2. Experimental protocol schematic. If no cramped occurred during first attempt, subject rested for 10 minutes and the protocol was repeated (maximum 5 attempts). Figure 3. Experimental set up. Six recording EMG electrodes were affixed to all three heads of the triceps surae. EMG and muscle force were continuously measured during MVC and throughout the muscle cramp. Ankle held in maximal plantarflexion Force transducer 12 hours 15 minutes ~5 minutes <90 seconds Muscle cramp 20 minutes 48 hours “I am not aware of any other consumer product that has demonstrated significant efficacy in mitigating muscle cramps in a rigorous double-blinded scientific study.” -- Dr. W. Larry Kenney, Professor at the Noll Laboratory at PSU Presented at Experimental Biology by PSU (April 2016) •  Oral consumption of a mixture of TRPV1 and TRPA1 agonists prior to exercise mitigated muscle cramp intensity and perceived soreness. •  Overall muscle activity during cramping (integrated area of EMG intensity-duration curve) was reduced with the active treatment. •  Self-reported ratings of muscle soreness were lower within the first 20 minutes after cramp cessation with the active treatment. Positive Effect on Athletic Human Muscle Cramps

 

28 Inspiring Origin Story While sea kayaking he suffered debilitating muscle cramps Rod the athlete was frustrated Rod the scientist set out to find a solution Nobel Prize winning neuroscientist Endurance Athlete

 

29 Digital Media

 

30 Print Media

 

31 Available within weeks •  Scientifically proven •  Premium value •  Retail presence in 3 markets •  Branded website •  Face-to-face events to cultivate influencers •  Authentic brand ambassadors •  Word of mouth amplified through social media Q2 Launch COMING SOON

 

32 Financial Profile •  NASDAQ: FLKS •  $84.4 M Cash balance as of 3/31/16 •  Cash through mid-2018 based on current operating plan •  ~17.9 million shares outstanding •  No debt

 

33 Novel Treatments for Neuromuscular Conditions NASDAQ: FLKS

 

34 Broad Intellectual Property Prosecuting several patent applications •  Methods and compositions for preventing, treating or ameliorating muscle cramping and/or accelerating nerve-muscle recovery from exercise fatigue •  Compositions of ion channel activators and methods of preparation, formulation, and the medical use of these compositions One provisional patent application filed in the U.S. •  Method and compositions for unwanted or abnormal muscle contraction (single and combination molecule TRP activators)